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Abstract: Although established clinical utility is of key importance in choosing agents for radionuclide therapy, other key 
factors include costs and GMP availability of sterile, pyrogen-free, regulatory approved radiopharmaceuticals. No-carrier-
added (NCA) 188Rhenium(188Re, 16.9 hour half-life; 155 keV gamma emission) is available on demand as 188Re-
perrhenate from saline elution of a 188Tungsten/188Rhenium(188W/188Re) generator. The availability and superb 
radionuclidic and chemical properties make 188Re an excellent candidate for radionuclide therapy. This radioisotope is 
readily attached to a variety of targeting agents and also emits high energy beta particles (Emax 2.12 MeV) for therapy. 
Over the last 30 years the effectiveness of 188Re for a variety of therapeutic applications has been established in multiple 
clinical studies. This overview provides a brief summary of clinical applications with 188Re-labeled agents as an 
introduction to the detailed clinical discussions in the following papers. Although 188Re-labeled radiopharmaceuticals for 
routine clinical use and accompanying reimbursement are not yet commercially available, several agents have been 
evaluated in clinical studies. In addition, a large number of 188Re radiopharmaceutical agents have been developed and 
evaluated in pre-clinical studies over the last three decades. This review focuses on providing examples of 188Re-labeled 
radiopharmaceutical agents which have entered late stage clinical use and have demonstrated good efficacy. These key 
applications include palliative treatment of skeletal metastases, intra-arterial therapy of liver cancer and post PTCA 
intravascular inhibition of arterial restenosis. Also, 188Re radiopharmaceuticals had been developed and initially assessed 
for synovectomy and for marrow suppression. More recently, a unique device-based technology has entered clinical use 
for therapy of non-melanoma skin cancer using a 188Re topical cream. Finally, 188Re-antibodies are being developed for 
the potential therapy of infectious disease and this unique new therapeutic strategy is expected to enter clinical trials in 
the near future. 
Keywords: Bone pain palliation, Cancer therapy, Liver cancer, Skin cancer, 188Rhenium, 188Tungsten/188Rhenium 
Generator. 
INTRODUCTION 
An earlier paper in this issue summarizes the 
development and use of the 188W/188Re radionuclide 
generator to provide no-carrier-added (NCA) 188Re for 
attachment to various radiopharmaceuticals for 
targeted therapy. This contribution provides a brief 
overview of several key 188Re radiopharmaceuticals 
currently in clinical use as well as agents for developing 
new 188Re therapeutic applications. Although various 
therapeutic radioisotopes have been evaluated in the 
clinical arena, many others represent promising 
candidates for evaluation (Table 1). 188Re represents a 
key therapeutic radioisotope which is readily available 
NCA from the 188W/188Re generator for which continued 
research interest spanning more than thirty years has 
been expressed by the research and clinical 
communities. In the last several years interest by the 
radiopharmaceutical community has evolved and the 
GMP manufactured generators are now available 
which provide NCA 188Re as an active pharmaceutical  
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ingredient (API, Table 1). The first reported patient 
studies with 188Re were limited to very specialized 
applications involving evaluation of 188Re distribution in 
the nervous system [1] and for irradiation of the choroid 
plexus and central nervous system [2]. Although 188Re 
is of interest for therapeutic applications because of the 
benefit of high energy beta emission (2.12 MeV), some 
early studies had actually focused on evaluation of this 
radioisotope for possible diagnostic applications [3-4]. 
Despite extensive research and the development of 
new technology and targeting strategies, the literature 
has really only reflected the regulatory approval and 
introduction of a limited number of therapeutic 
radioisotopes/radiopharmaceuticals for routine clinical 
use (Table 1). As described in an earlier paper in this 
issue of IJNMR, in addition to the goal of decreasing 
188Re unit dose costs by optimization of generator use, 
the assured routine availability of reactor-produced 
188W and 188W/188Re generators are two key issues 
which must be further addressed as well. Use of the 
188W/188Re generator system is particularly well suited 
for use in more remote areas and in developing regions 
where the logistics and high costs of regular 
radioisotope importation are important issues. 
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Realization of the benefits for clinical use of 188Re in 
developing regions was promoted by Dr. A. J. Padhy in 
the Nuclear Medicine and Diagnostic Imaging Section 
of the International Atomic Energy Agency (IAEA), 
which had teamed with ORNL in the early 1990’s and 
various research centers to explore this possibility. 
Multi-institutional clinical projects were established for 
support of two key clinical programs focused on the 
use of various 188Re agents for the transarterial therapy 
of non-resectable liver cancer [5-7] and for post 
angioplasty treatment for inhibition of coronary 
restenosis using 188Re-liquid-filled balloons [8]. The 
very successful Thematic Program on Health Care 
project (Asia and Pacific Region, RAS/6/028) entitled 
“Management of Liver Cancer Using Radionuclide 
Methods With Special Emphasis on Trans-Arterial 
Radio-Conjugate Therapy and Internal Dosimetry” [6], 
was initiated in 2000, and represented the first IAEA-
sponsored doctoral program. At the same time, these 
IAEA efforts were effectively coordinated through 
various Coordinated Research Project (CRP) programs 
organized by the IAEA Industrial Applications Section, 
which supported basic science studies for evaluation of 
188W production, development of new 188W/188Re 
generator prototypes, and for the development and pre-
clinical evaluation of a variety of 188Re-labeled 
radiopharmaceutical agents. The two 188Re applica- 
tions which have moved further forward into the clinical 
arena include the use of 188Re-labeled agents for 
treatment of inoperable hepatocellular carcinoma 
(HCC) and for palliation of metastatic bone pain with 
188Re-HEDP. The goal of this paper is to provide an 
overview of the use of 188Re-labeled therapeutic agents 
for the treatment of several clinically relevant conditions 
for targeted therapy with beta irradiation. In addition to 
the therapeutic benefits of the 188Re high energy 2.12 
β- emission, the accompanying 155 keV gamma 
photon emission allows important theranostic benefits, 
for determination of biodistribution and biokinetics to 
evaluate dosimetry and to potentially correlate 
biodistribution with therapeutic response. Since the 
published literature describing the development and 
use 188Re-labeled agents is becoming quite extensive, 
only snapshots of these technologies are described in 
this paper. As described in more detail in the 
accompanying paper, 188Re is generated by beta-decay 
of 188W, and conveniently obtained by saline elution of 
the 188W/188Re generator system, prepared using 
reactor-produced 188W obtained by the 186W(2n,γ)188W 
route. The generator system is usually installed in-
house and represents a very convenient, cost effective 
and on demand source of 188Re. The eluted sodium 
188Re-perrhenate is then available for radiopharmacy 
preparation of various 188Re-labeled therapeutic agents 
using chemistry similar for the introduction of 99mTc into 
diagnostic agents. Generally, generator activity levels 
of 0.5-1 Ci are commercially available, and in some 
cases, as GMP manufactured sterile systems. 
Currently, GMP-manufactured non-sterile generators 
are available from Isotope Technologies, in Munich, 
Germany, and from the JSCSSC RF-IPPE Institute in 
Obninsk, the Russian Federation. A GMP-produced 
sterile generator system equipped with a disposable 
188Re post elution concentration module is available 
from IRE-Elit, in Fleurus, Belgium (Knapp, Table 1). 
1. KEY CURRENT CLINICAL APPLICATIONS WITH 
188RHENIUM-LABELED RADIOPHARMACEUTI- 
CALS 
1.1.188Rhenium-Hydroxyethylidene Disphosphonate 
(HEDP) 
188Rhenium-HEDP is the key agent which has 
evolved into further clinical studies from an impressive 
series of agents and strategies which have been 
developed and evaluated for the use of 188Re-labeled 
agents for the treatment of metastatic bone pain. The 
first clinical studies with 188Re-HEDP were reported in 
1998 by Maxon [9-10], where the biodistribution and 
radiation dosimetry characteristics determined in 
preliminary studies in patients with skeletal metastases 
following intravenous administration of a 30 mCi dose 
(1110 MBq0) provided benefits and toxicity similar to 
data reported previously for 186Re-HEDP. These 
investigators noted the expected benefits of on-
demand availability of 188Re from the 188W/188Re 
generator and in-house preparation (Figure 1) of 188Re-
HEDP for treatment on an outpatient basis which has 
now evolved to a “kit”-based preparation. The ready 
availability of NCA 188Re on demand from the 
188W/188Re generator is an important technical and 
operational convenience which catalyzed the 
evaluation of several other agents for bone pain 
palliation based on 188Re. Although 188Re-labeled 
hydroxyethylidene diphosphonate (188Re-HEDP) is the 
only 188Re-labeled agent for bone pain palliation which 
has evolved for broader clinical use, other examples of 
188Re-labeled bisphosphonate ligands have been 
prepared and evaluated in pre-clinical studies. 
Examples of these 188Re-phosphonate analogues 
which have been reported for potential metastatic bone 
palliation include dipicolymine alendronate [11], 
ethylenediamine-N,N,N′,N′- tetrakis (methylene 
phosphonic acid) [12] and 2-sulfonato-1,1-ethylidine 
bisphosphonic acid (SEDP) [13]. Evidently these 188Re-
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phosphonate-based agents have not progressed to 
clinical studies. 
Although other 188Re phosphonate analogues have 
been evaluated but have evidently not yet progressed 
Table 1: Key Examples of Beta-Emitting Radioisotopes of Current Interest for Radiotherapy 
Radioisotope 
Production 
Availability 
Principal 
Emissions 
keV 
Approved for 
Routine Clinical 
Use 
Comment * 
Reactor produced, available from batch production/processing 
Radioisotope 
Half-Life 
Gammas 
keV (%) 
β- Emax MeV 
% Intensity   
169Erbium 
.4 d 
Very low 
Energy/int. 0.351 Yes Clinical use limited to RS of small joints 
166Holmium 
1.1117 d 80.6, 6.2 % 1.850, 50% No 
Many early stage clinical trials have been described. Also 
available from the 166Dy(n,γ)166Ho generator (below) 
131Iodine- 
8.02 d 364, 81%  0.606, 89% Yes Widely used, thyroid cancer ablation, antibodies, etc. 
177Lutetium 
6.68 d 497, 78 % 2.080,11% Yes
 
177LuCl3 now available as “LuMark®” 
from AAA for Lutathera (DOTATATE) 
EndolucinBeta® from ITM,  
precursor for DOTATAE  
177Lu-617 targeted to PSMA, FDA approved for 
RadioMedix clinical trials 
186 Rhenium 
3.72 d 137, 8.6% 1.069, 80%  No  Re-186-HEDP withdrawn 
188Rhenium- 
16.9 h 
 155, 15%  
 
2.120, 71% No Although usually available from the generator (See below) can also be produced from 187Re(n,γ)188Re route 
153Samarium 
2.0 d 103, 28% 0.808, 17%  Yes
 153Sm-EDTMP commercially available as an approved 
agent and widely used for bone pain palliation 
Generator or accelerator produced 
166Holmium 80.6, 6.2 % 1.850, 50% No RG, from 166Dy decay 
188Rhenium 
16.9 h  155, 15%  2.120, 71% No 
RG, from 188W decay Multiple clinical trials in progress, 
Inter alia 
90Yttrium- 
64.1 h No γ’s 2.280, 99.9% Yes 
RG, from 90Sr decay 
Peptide/antibody therapy 
*RS = radiation synovectomy; R = reactor; A = accelerator; RG = radionuclide generator; AAA = Advanced Accelerator Applications; ITM = Isotope Technologies 
Munich; PSMA = prostate specific antigen. 
 
 
Figure 1: Schematic summarizing the preparation of 188Re-HEDP. 
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to evaluation in the clinical arena, the188Re-
dimercaptomethylsuccinic acid (188Re-DMSA) non-
phosphonate-based 188Re-labeled agent (Figure 2)  
[14-20] had also been developed and evaluated for 
treatment of metastatic bone pain. This agent was 
developed for potential therapy of various tumors as a 
“matched pair” to 99mTcDMSA, which had demonstrated 
uptake in medullary carcinomas of head and neck, and 
medullary tumors [16]. This 188Re-DMSA agent is 
unique since different stereoisomers are formed during 
radiolabeling with 188Re. A very nice subsequent study 
isolated the multiple/three 188Re-DMSA isomers 
prepared by stannous ion reduction by high 
performance liquid chromatography [19]. Evaluation of 
each of the isomers in animals studies, showed no 
differences in localization. This was a potential 
important benefit which meant that isomer separation 
would not have been required to optimize dosing and 
for potential further clinical evaluation of this agent for 
bone pain palliation. Systematic evaluation of the 
isomeric mixture of 188Re components was followed by 
early phase safety and therapeutic studies in patients 
[14, 18]. In addition to the several papers which had 
described the synthesis, evaluation of the isomers, and 
pre-clinical evaluation of the, 188Re-DMSA agent 
showed excellent localization in skeletal metastases, 
as may have been suspected from the localization of 
metastasis from breast carcinoma using 99mTc-DMSA. 
Subsequent clinical studies demonstrated high specific 
uptake 188Re-DMSA in skeletal metastases, indicating 
possible use for therapy of skeletal metastases from 
prostatic carcinoma [18] and possibly from other 
primary carcinomas. However, because of high renal 
uptake the 188Re(V)-DMSA agent has not been further 
evaluated for therapeutic efficacy in clinical studies.  
 
Figure 2: Structure of 188Re-dimercaptomethylsuccinic acid 
(DMSA). 
Subsequent studies focused on an evaluation if pH 
levels affected renal uptake. With the “matched pair” 
99mTc(V)-DMSA analogue, for instance, increased pH 
values reduce renal uptake [20]. In order to assess the 
importance of the reducing agent for the 
Re(V)→Re(VII) reduction step, other investigators 
showed that 188Re(V)-DMSA prepared by reduction 
with sodium meta-bisulfite demonstrated less renal 
uptake in animal studies [21-22] and that such 
complexes mixtures consisted of different isomer 
ratios. Interestingly, the complex prepared by the usual 
stannous reduction exhibited more prolonged skeletal 
retention. Although vascular clearance was the same 
for both preparations, kidney retention was greater for 
188Re(V)-DMSA prepared using stannous anion 
reduction. This may explain the differences observed in 
the relative biodistribution results between the 
188Re(V)-DMSA products prepared by the two different 
reducing agents. So in spite of some very careful and 
promising developmental studies, apparently despite 
the promising results of Blower and others, the clinical 
use of 188Re-DMSA has not progressed further. 
The 188Re-HEDP agent moved forward in several 
clinical studies for bone pain palliation because of its 
efficacy, ease of preparation and low toxicity. Data from 
several very promising studies have been reported 
using 188Re-HEDP [23-28] This agent shows good 
clinical efficacy and demonstrates pain palliation results 
similar to data described for phosphonate analogues 
radiolabeled with other beta-emitting radionuclides 
(153Sm and 186Re) and 89Sr chloride [28] in patients 
presenting with metastatic bone disease form 
metastases from prostate, breast and lung cancer. As 
an example, 61 patients presenting with skeletal pain 
from bone metastases from cancer of the bladder, 
breast, kidney, lung, and prostate, were treated with 
doses of 31-188 mCi [23]. Good efficacy and overall 
pain relief of 80% with no evidence of hematopoietic or 
severe side effects were observed after one year. A 
response rate of 76% was reported from another study 
in which 27 patients with hormone refractory prostate 
cancer were treated with188Re-HEDP [24]. Similar 
efficacy has also been observed treating patients with 
metastatic bone from lung cancer [25] and several 
other clinical studies with 188Re-HEDP. A larger 
controlled study conducted in Bonn, Germany, focused 
on repetitive treatment, where a single dose or 
repeated doses of 188Re-HEDP were administered to 
64 patients. In addition, to slightly better pain relief, 
more importantly, repeated dosing with 188Re-HEDP 
resulted and in an apparent therapeutic effect [24].  
More recently, these authors in Bonn had 
retrospectively evaluated and compared the data from 
this study using single and multiple administrations of 
(188Re-HEDP) on palliation and survival of prostate 
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cancer patients presenting with more than 5 skeletal 
metastases [29]. The 188Re-HEDP was prepared using 
NCA 188Re obtained from an in-house generator 
following dilution with carrier perrhenate. Although the 
use of high specific activity radiopharmaceuticals is a 
usual goal, it is important to note that the use of 188Re-
HEDP is a unique example where the Re specific 
activity must be decreased in order to provide sufficient 
mass for targeted uptake by an unknown mechanism. 
The data available for the 60 patients included PSA 
levels and Gleason scores, which were similar for the 3 
groups, which consisted of Group A (n = 19) in which 
patients had received a single injection, Group B (n = 
19) patients who had 2 injections and Group C (n = 22) 
in which patients had received 3 or more successive 
injections. When significant pain palliation was 
observed, it was independent of administration 
frequency. The mean 95% confidence interval survival 
data calculated from initiation of treatment were 4.50 ± 
0.81 months for Group A (2.92-6.08), 9.98 ± 2.21 
months (5.65-14.31) for group B, and 15.66 ± 3.23 
(9.33-22.0) for group C. Values for pain palliation were 
89.5% (Group A), 94.7% (Group B) and 90.9% (Group 
C). The number of lost life-years was significantly lower 
in Group C than the other two groups, although the 3 
groups did not differ in Gleason score. An important 
observation was the 4.50 to 15.66 month improvement 
in post-treatment overall survival for multiple-injections 
in comparison with a single injection of 188Re-HEDP. 
These studies in Bonn and similar studies by Liepe  
et al. with 188Re-HEDP in Kassel, Germany, and also 
elsewhere, had clearly demonstrated that in house use 
of the 188W/188Re generator is feasible and allows on 
demand and cost-effective access to the excellent 
188Re-HEDP agent for bone pain palliation. 
These combined clinical date have thus clearly 
demonstrated that efficacy using 188Re-HEDP [28] is 
similar to other bone pain palliation agents radiolabeled 
with 186Re and 153Sm. There is also great interest in the 
possibility of enhanced synergistic effects by 
administration of chemotherapeutic agents and 
targeted radiopharmaceuticals radiolabeled with beta-
emitting radiopharmaceuticals. Some studies have 
suggested synergy by evaluation of the combined 
efficacy of chemotherapy and radiation damage from 
188Re-HEDP. In a Phase I study, 188Re-HEDP (1 
mCi/kg) was intravenously administered after a 14 day 
increasing (<2,500 mg/m2 total) oral dosage of 
capacitabine (Xeloda®) to prostate cancer patients (3 
patients/in two cohort) with bone metastasis refractory 
to hormone therapy [30]. The results demonstrated that 
capacitabine has no apparent effect on 188Re-HEDP 
biodistribution and excretion. Although unacceptable 
toxicity was observed in this initial MTD study, 
evidently, a Phase II study has been proposed to 
continue evaluation of the efficacy and potential 
synergistic effects of these two therapeutic strategies. 
More recently, similar combined effects of 188Re-HEDP 
and taxanes have been reported in human prostate 
carcinoma cells in vitro [31].  
Although the earlier routine effective clinical use of 
188Re-HEDP spanned over several years in Germany 
(Bonn and Kassel) and elsewhere, use of this agent at 
these centers is evidently not currently in progress. 
However, recent renewed interest in the benefits of 
using 188Re-HEDP for treatment of intractable skeletal 
pain form metastases are reflected in the efficacious 
reports of studies in progress at the Meander Medical 
Center in The Netherlands [32-36] and in Coimbatore, 
India [37]. At the Meander Center, in house routine 
GMP production of 188Re-HEDP had been instituted 
[32-36] and over 200 patients have been treated with 
188Re HEDP at this institution (R. Lange, personal 
communication). In studies conducted at the 
Comprehensive Cancer Centre at the Kovai Medical 
Centre in Coimbatore, the clinical efficacy of 188Re-
HEDP is also being evaluated [37]. Of particular 
importance for radiopharmacy preparation, several “kit” 
preparations have also been described for the 
preparation of 188Re-HEDP for patient administration 
[39-43]. 
1.2. 188Rhenium Labeled Particles for Transarterial 
Therapy of Hepatocellular Carcinoma (HCC) 
Because of the widespread occurrence of 
inoperable hepatocellular carcinoma (HCC), especially 
in developing countries, the availability of cost effective 
radioactive therapeutic agents often offers the only 
option for these patients. For this reason, many 
approaches and technologies are being evaluated and 
the trans-arterial administration of therapeutic 
radioisotopes for trapping in the micro vascular of the 
tumor feeding arteries is an important accessible option 
for patient treatment and management. Interest in this 
therapy area has seen the evolution of several 188Re-
labeled agents, because of attractive radionuclidic 
properties and on demand availability. Several 188Re-
labeled Lipiodol-based agents have thus been 
developed and evaluated for this important application 
(i.e. IAEA trial) [44-49]. The development of 
radiolabeling “kits” [50-53] and impressive clinical 
experiences with this agent [54-85] have been 
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described. Also, various 188Re-labeled microsphere 
preparations have been described as administration 
vehicles [86-91], “kits” have been developed [90] and 
patient studies reported [92-95]. Lipiodol is an 
ethiodized plant oil containing iodine and combined 
with very lipophilic fatty acid ethyl esters has been 
traditionally used for many years as a myelographic 
contrast agent. For therapy, 131I-Lipiodol was 
developed for hepatic arterial administration, shows 
prolonged hepatic retention, and is widely used for 
HCC therapy [96-97]. Incorporation of the therapeutic 
131I radioisotope by exchange of the nonradioactive 
iodine had offered an opportunity to irradiate the tumor 
in addition to interfering with blood flow. However, this 
agent is difficult to prepare, can be unstable and 131I 
emits high energy photons so significant radiation dose 
may not localized just to the desired treatment site.  
188Rhenium was recognized several years ago as 
an attractive alternative candidate to the use of 131I for 
HCC targeting therapy because of its inexpensive 
availability on-demand from the 188W/188Re generator 
and a variety of 188Re-labeled Lipiodol analogues have 
been prepared and evaluated. Although the use of 
188Re-labeled microspheres had appeared to be an 
attractive strategy because of the ease of preparation 
and particle stability [86-90], most approaches have 
focused on the combination/suspension of a very 
lipophilic 188Re-labeled complexes with Lipiodol. One 
early approach involved suspending the readily 
prepared 188Re-sulphur colloid in Lipiodol [98], while 
other approaches used the 188Re-ECD agent for 
Lipiodol suspension. However, none of these agents 
have progressed to more expanded clinical studies, 
and a more focused approach [99] involved the very 
lipophilic 188Re-TDD agent (2,2,9,9-tetramethyl-4,7-
diaza-1,10-decane dithiol) agent initially developed and 
used in the IAEA-supported trials and had been used in 
several clinical trials (Figure 3). Afterwards, the more 
lipophilic 188Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-
diaza-1,10-decanethiol (188Re-HDD) agent had evolved 
from these investigators and was introduced for clinical 
use at several institutions [100-105]. To assess 
efficacy, 188Re-HDD has been compared to 131I-lipodol 
in a comparative evaluation in patients suffering from 
inoperable HCC [100]. The importance of this study 
demonstrated that 188Re-HDD/lipiodol resulted in a 
cytotoxic effect and a lower radiation exposure for an 
expected higher tumor-killing effect than 131I-Lipiodol. 
Under the leadership of Dr. A. J. Padhy, the 
International Atomic Energy Agency (IAEA) then 
prepared a protocol and conducted a multi-country 
Phase I/II clinical trial with 188Re-HDD-Lipiodol 
demonstrating three complete responses and 19 partial 
responses in 185 patients in eight countries [5-7]. 
Further studies in a Coordinated Research Project 
(CRP) organized and funded by the International 
Atomic Energy Agency (IAEA) included a single HCC 
patient evaluation using 188Re-HDD-lipiodol to evaluate 
dosimetry [101-102] where the maximum safely 
tolerated patient activity was estimated to be 
approximately 225 mCi (8511 MBq). The lungs were 
the dose limiting organ and most importantly, two 
doses of 188Re-HDD-lipiodol resulted in complete 
disappearance of a large volume tumor and the patient 
 
Figure 3: Chemical structures of 188Re-labeled lipophilic agents for admixture with Lipiodol for transarterial administration for 
HCC therapy. 188Re-(V)-HDD [188Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol]. 188Re-(V)-DEDC [188Re-nitrido 
bis(diethylthiocarbamate)]. 188Re-(III)-SSS-lipiodol [SSS = (S2CPh)(S3CPh)2]. 
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was disease free for 18 months. Subsequently, this 
group reported a large scale clinical trial involving 93 
patients in India and Vietnam using 188Re-HDD-lipiodol 
[103]. In Ghent, Belgium, studies confirmed that 28 
patients receiving 35 treatments of 188Re-HDD-lipiodol 
with activities ranging from 130-190 mCi tolerated the 
dose with no severe complications [104-105]. A 
significant reduction in AFP levels was measured in 
patients six weeks after treatment, and a response 
assessment showed partial response in 1, stable 
disease in 28, and disease progression in 2 treatments.  
The use of 188Re for the treatment of HCC is also in 
progress in Rennes, France, where preparation of a 
third agent - 188Re(III)-SSS-lipiodol [SSS = 
(S2CPh)(S3CPh)2] (Figure 3)– has been developed [47-
49]. Initial studies described the synthesis of this highly 
lipophilic agent and formation of the 188Re(III)-SSS-
lipiodol complex [59]. Studies in a porcine model [58] 
and a comparative evaluation of 188Re-SSS-lipodol with 
131I-Lipiodol in rats bearing experimental hepatocellular 
carcinoma tumors demonstrated the expected more 
positive results from irradiation of the small rat tumors 
[59]. A summary of the Phase I open-label clinical trial 
at Rennes with 188Re-SSS/Lipiodol is described in the 
US NIH directory (https://clinicaltrials.gov/ct2/show/ 
NCT01126463). The combined evaluation of clinical 
studies with 188Re-lipiodol agents have shown that this 
strategy is efficacious, although two issues which must 
be further improved, include increasing the 188Re 
radiolabeling efficiency and in vivo stability of these 
agents to minimize liver leakage of activity and 
potential radiation exposure of non-target tissues.  
Another approach for HCC therapy with 188Re has 
described the preparation of the 188Re-nitrido bis 
(diethylthiocarbamate) (“DEDC”) agent as an 
alternative agent with increased radiolabeling yields 
[45]. The “kit” preparation of (DEDC) complex involves 
188Re(V) which is attached to nitrogen as a nitrile 
linkage (Figure 3) [51-53]. Use of an automated 
synthesis module insures reproducible preparation of 
188ReN-DEDC-lipiodol and preparation of the Lipiodol 
mixture and reduces user radiation dose [106]. The 
188ReN-DEDC complex is highly lipophilic and is 
quantitatively extracted into lipiodol forming the 
administration mixture. With appropriate administration 
the 188ReN-DEDC-lipiodol complex demonstrates good 
in vivo stability, shows selective tumor localization and 
results in impressive target/non-target tissue ratios 
[106, 107]. Initial clinical trials showed that 188Re-DEDC 
could be a useful radiopharmaceutical for unresectable 
HCC therapy. As another example, preparation and 
pre-clinical evaluation have also been reported for 
188Re(N)(cys) (PNP), which is another example of a 
Re(V) nitrido complex, but clinical studies with this 
congener have evidently not yet been pursued [108].  
Finally, the combined synergistic application of 
188Re-HEDP and other agents with chemotherapeutic 
agents may develop further. As an example, a recent 
Phase I safety study evaluated the combination of 
188Re-HEDP with capecitabine in patients with hormone 
refractory prostate cancer where 17 patients were 
treated with 188Re-HEDP and different doses of 
capecitabine [30]. Preclinical studies have also 
evaluated the In vitro effects of both gemcitabine and 
5-fluorouracil and 188Re [106] and the spectacular 
supra additive effects of cytotoxic drugs and 188Re in an 
in vitro model of HCC, demonstrating that the potential 
importance for further exploration of combined 
therapeutic approaches using 188Re agents and 
targeted toxic agents may offer increased therapeutic 
effectiveness. More recently, combinational studies 
using soranfenib in a hepatoma cell line have shown 
positive results, [109, 110]. 
Continuation and expansion of the clinical use of 
such Lipiodol mixtures of these radiopharmaceuticals 
and potentially other 188Re-labeled agents for the 
therapy of inoperable HCC is expected to continue, 
however, GMP commercial availability of such agents 
would be expected for wider use. The extensive earlier 
international clinical experience during the IAEA-
supported international trial has recently served as the 
foundation for use of 188Re-agents for current treatment 
of HCC in Coimbatore, India, and at several other 
centers. 
2. EXAMPLES OF PIONEERING CLINIAL STUDIES 
WHERE 188RHENIUM LABELED AGENTS PLAYED 
KEY ROLE FOR TECHNOLOGY DEVELOPMENT 
2.1. Inhibition of Arterial Re-Stenosis Following 
PCTA 
Percutaneous transluminal coronary angioplasty 
(PTCA) is a common treatment mode for patients 
suffering from artherosclerotic coronary artery disease 
where balloon inflation at the stenotic site restores flow 
(Figure 4). However, because of the wound healing 
biological response to vessel damage, the resulting 
smooth muscle cell proliferation often results in the 
occurrence of restenosis in as high as 30–50% of the 
patients post angioplasty. For this reason there has 
been extensive, aggressive research to develop 
technologies which would effectively reverse the 
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incidence of coronary restenosis after PTCA. One 
important and successful strategy had been the use of 
radioisotopes emitting ionizing radiation to inhibit 
smooth muscle proliferation for this new “intravascular 
radionuclide therapy (IVRT)” method. A key example 
has been the use of 188Re-liquid filled balloons for 
restenosis therapy which had been rapidly embraced in 
the 1990’s by the interventional community. Single site 
clinical trials were initially conducted at the Cedars 
Sinai Medical Center in Los Angeles (Dr. Neil Eigler, et 
al.) [110-112] and at the Columbia University/ 
Presbyterian Hospital in New York City (Dr. Judah 
Weinberger, et al.) [113-121]. Subsequent initiation of 
clinical trials with this approach quickly followed in 
several countries (including Australia, Germany, Korea, 
Taiwan, etc.). A dedicated journal (Cardiovascular 
Radiation Medicine) was also introduced by Elsevier, 
which was published during the 1999-2004 period, but 
which had ceased publication when this technology 
was subsequently usurped by the use of drug eluting 
stents. The IAEA-supported trial also had high hopes, 
but because of the limited infrastructure available at 
many sites, introduction of this technology for the use 
of 188Re-liquid filled balloons did not flourish and move 
forward as expected.  
During this intense period of developed and 
evaluation, several companies were also established 
which were dedicated to the use of beta emitting 
radioisotopes for this unique application and launched 
effective technologies (192Ir, Novoste; 188Re, Vascular 
Therapies, etc.). It is impressive that such a large 
number of peer-reviewed papers had been published 
during this short time period in high level journals on 
this unique application use of 188Re-intravascular 
therapy techniques.  
The common occurrence of smooth muscle 
hyperplasia leading to arterial restenosis following 
balloon angioplasty is an unavoidable and well 
established complication associated with interventional 
procedures resulting from vascular hyperplasia in 
response to vessel wall damage (Figure 5). Until 
relatively recently, the use of intravascularly placed 
beta-emitting radioisotope sources was in fact the only 
successful therapeutic approach to overcome this issue 
until the introduction of drug-eluting stents [122-123]. 
Evaluation of various radioisotopes and delivery 
approaches had rapidly progressed to clinical trials and 
included the use after-loader placed 192Iridium- (192Ir) 
wires and ribbons advanced through in-dwelling 
catheters, 32Phosphorus (32P) coated balloons and the 
use of 188Re (188Re) liquid-filled balloons, involving 
manual filling of a balloon with subsequent filling with 
188Re solution placed following angioplasty [110-121]. 
Use of the liquid-filled balloon offered a special bonus 
for the most effective approach for uniform vessel wall 
irradiation. Because of the rapid fall off of beta particle 
energy with radial distance, the use of solid sources 
was challenged by the difficulty of luminal centering. 
The difficulty in accurate luminal centering of the 
radioactive source would result in unavoidable 
consequence of non-uniform vessel wall irradiation, 
since reduced irradiation dose delivery (i.e. solid 
     
Figure 4: Left. Cartoon illustrating of the smooth muscle cell hyperplastic wound healing response to vessel damage from 
coronary balloon angioplasty and the use of post PTC irradiation for inhibition of restenosis. Right. Illustration of damage to 
intima from high pressure balloon inflation (With permission of the Editor, Science and Medicine, Vol. 3(3), 1996). 
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source more distant than from contralateral wall) would 
stimulate smooth muscle cell hyperplasia. The 
advantages and eloquence for using the 188Re liquid 
filled balloon thus included a de facto uniform contact 
with and thus uniform irradiation of the target wall 
region. Figure 5 illustrates the effectiveness of this 
strategy for inhibition of smooth muscle hyperplasia 
after balloon inflation in a porcine model. The obvious 
benefits of using the 188Re-liquid filled balloon strategy 
thus generated wide-spread interest, and a large 
number of patients were subsequently treated with this 
therapy at centers in the Australia, Germany, Korea, 
Taiwan, and other countries, at self-funded single 
centers and in conjunction with the International Atomic 
Energy Agency (IAEA) established a Coordinated 
Research Project (CRP) in countries promoted and 
funded by Dr. A. Padhy, using generators available 
from ORNL.  
The use of 188Re-perrhenate for balloon inflation 
was first proposed for liquid balloon-filled inflation [124-
135] and was then successfully introduced for clinical 
use [110-121]. Since possible unexpected balloon 
rupture would result in vascular release of 188Re-
perhenate and potential high thyroid and radiation 
exposure, animal studies evaluated thyroid pre-
blocking and also post rupture displacement of 
perrhenate. These studies demonstrated that 
prophylactic pre-blocking with iodide (Lugol’s) [136] 
and post thyroid displacement of 188Re-perrhenate with 
perchlorate [137] effectively protected the thyroid from 
radiation exposure and one clinical case did report 
balloon leakage of 188Re [138]. Preparation and initial 
clinical evaluation 188Re-complexes that demonstrate 
high renal clearance as well as several hydrophilic 
complexes is another reported approach [139-147]. For 
the use of radioactive liquid filled balloons such as 
188Re, a close association was required between the 
interventionalist and nuclear medicine or radiation 
oncology physician administering the radioactive 
source for the successful use of this technology. Of 
particular importance is an accurate estimate of the 
dose prescription, which is accomplished with real time 
use in the catheterization suite of specially developed 
software using the balloon dimensions and lesion 
characteristics [148]. 
Several clinical studies had used various 188Re-
labeled species for post angiographic treatment of 
arterial segments which initially, which included 188Re 
sodium perrhenate (188ReO4-2) obtained by direct 
physiological saline elution of the 188W/188Re generator 
[111-121]. Use of 188Re-perrhenate represented the 
most direct and simple route to obtain 188Re, since 
perrhenate is exclusively and rapidly excreted via the 
urinary bladder in the very unlikely possibility of balloon 
rupture/leakage. Leakage of 188Re from a perrhenate-
filled balloon study was reported in one clinical case 
[138] but dosimetric analysis indicated no unacceptable 
radiation dose had been received. Several studies 
substantiated that thyroid localization of perrhenate 
could be blocked and displaced by treatment with 
Lugol’s (NaI, sodium iodide) solution or with 
perchlorate [136-137]. Investigators also evaluated the 
preparation and clinical use of the 188Re-MAG3 complex 
[140-146] and 188Re-labeled DTPA (diethylene 
triaminepentaacetic acid) agents [147, 149-150], and 
preparation of the ethylene dicysteine complex (EC) 
[150], as an added precaution, since the rapid urinary 
bladder excretion of both of these agents is well 
established in the unlikely event of balloon rupture (< 1 
in 10,000)].  
 
Figure 5: A swine coronary model illustrating balloon overstretch damage to a control vessel (a) compared with the 
effectiveness of post-vessel damage irradiation with a 188Re-MAG3 liquid filled balloon (b). 
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Several studies had shown the positive results from 
using this technology. As one example, post 
angiographic analyses of 113 patients who had 
received 22.5 Gy [151-152] in a group of 225 patients 
using 188Re liquid-filled balloons demonstrated that the 
target vessel revascularization rate was significantly 
lower in patients who had received radiation in 
comparison with data from 112 patients in the control 
group [154]. Although the data from such a small 
number of patients did not permit an accurate analysis, 
in another study a six-year clinical follow-up study after 
treatment with 188Re filled balloon showed that the 
restenosis was lower in the case of 188Re patients as 
compared to the controls [153, 155]. Unfortunately, 
IVRT with 188Re-liquid filled balloons or use of other 
radioisotopes never developed to the promise that it 
offered due to the introduction and preferred use of 
drug coated stents. The results of typical trials resulted 
in significantly reduced incidence of restenotic 
segments compared to controls. Also, impressive 
angiographic data were still maintained in studies 
evaluated 2→6 years post treatment [149, 153-158]. In 
spite of the impressive results from this multiple 
studies, use of this technology for coronary vessels 
was rapidly abandoned with the introduction of drug-
eluting stents.  
More recently, however, this technology had been 
further developed and successfully extended for the 
treatment of restenosis of the peripheral arteries  
[159-161], using a device and technology developed by 
Flowmedical®, in Garching, Germany. ITM Munich had 
received full CE-certification and approvals for the 
rhenium-PTA and PTCA in September 2008 
(http://www.itm.ag/content/view/49/92/). Despite 
several published studies with promising results, it is 
unclear if clinical use of this technology for the 
peripheral arteries is continuing. In addition, preliminary 
studies have also reported the use of 188Re-liquid filled 
balloons for the successful treatment of refractory 
benign airway strictures [162] and keloids [163]. 
Apparently these studies have not further proceeded, 
but the positive results further illustrate the usefulness 
for inhibition of re-closure from smooth muscle 
hyperplasia can be avoided by radiation therapy in 
areas accessible by catheters for balloon inflation. 
Impressive results from several other IVRT studies 
have also been reported [163-184], before use of this 
technology using the 188Re liquid-filled balloons was 
transcended by use of drug-eluting stents for 
restenosis therapy of both the coronary and peripheral 
arteries. 
In fact, the effectiveness of the drug eluting stent 
and 188Re-IVRT technologies are evidently very similar 
for the inhibition of arterial restenosis after PTCA. 
However, use of non-radioactive technologies which 
can be conducted in routinely available facilities of 
course has many practical advantages over techniques 
which require the availability, use and disposal of 
radioactive materials. The use of radioactive sources 
also requires special precautions, training and often the 
complementary involvement of staff with board 
certification in nuclear medicine or radiation oncology. 
Although an effective and productive symbiotic 
relationship between interventional and nuclear 
medicine/radiation oncology physicians at a number of 
institutions, this technology had unfortunately never 
really been embraced by the nuclear medicine 
community, and been essentially abandoned with the 
introduction of drug-eluting stents. However, use of 
these radioisotopic strategies for restenosis therapy 
represents an important chapter in understanding the 
effects of post PTCA occlusion and paved the way for 
the introduction of more recent technologies. 
2.2. Radionuclide-Based Synovectomy with 
188Rhenium Labeled Agents 
The use of radiopharmaceuticals containing beta-
emitting radioisotopes for synovial irradiation via intra-
articulation for treatment of rheumatoid arthritis is a 
well-established nuclear medicine procedure which is 
widely practiced worldwide. It is interesting, however, 
that the US FDA has always questioned the possibility 
of radionuclide leakage and irradiation of non-target 
tissues as the key factor why they would not be 
expected to approve such a technology for clinical use 
in the US, although the first studies had been described 
in the U.S. Many different radioisotopes have been 
evaluated in animal and clinical studies and 
commercially approved radioisotopes and preparations 
used for this therapy include 169erbium-(169Er) (Table 1, 
for small joints), 186 Rhenium-(186Re, for medium size 
joints) and 90yttrium (90Y, for large joints). Because of 
attractive radioisotopic and chemical properties, and 
generator availability, several radiopharmaceutical 
preparations continuing 188Re have also been 
prepared, evaluated in animals and studied in humans 
[185-196]. The use 188Re has been very attractive and 
used in a variety of studies, since the high energy β- 
particles are especially useful for treating larger joints 
such as the knee. Inert vehicles for intra-articulation 
which have suitable biological properties for application 
in radiosynovectomy as seen in animal experiments to 
which beta-emitting radioisotopes have been attached 
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hydroxyapatite particles [191-192], microspheres [193-
194] and rhenium colloids [195]. The results of a 
number of clinical studies have been reported [186-
190] using 188Re-labeled agents for this application but 
presumably because of the broad availability of 
approved agents for the same application, use of the 
188Re agents had not progressed to routine use.  
2.3. 188Rhenium Labeled Antibodies for Marrow 
Suppression 
Rhenium-88-labeled antibodies have also been 
widely studied, although these agents have not entered 
routine clinical use [196]. One application using 188Re 
peptide/antibodies which that been explored on a 
clinical basis in some detail is the impressive results of 
bone marrow ablation with a 188Re “directly” labeled 
NCA 95 antibody anti-CD20 (anti NCA95) [197-203] 
which was evaluated as an adjuvant for conditioning of 
leukemia therapy. In spite of excellent myeloablative 
results the further use of this agent, however, has 
evidently not continued because of the unfortunate 
persistently high renal radiation doses. Because of the 
cost-effective routine availability of the 188W/188Re 
generator and facile preparation of directly 188Re-
labeled anti CD20, this approach may still have 
promise if methods become available that could 
significantly increase renal clearance.  
3. EXCITING NEW THERAPEUTIC STRATEGIES 
USING 188RHENIUM LABELED AGENTS  
3.1. Rhenium-188 Treatment of Non-Melanoma Skin 
Cancer 
A new device-based 188Re brachytherapy 
technology could provide enormous benefit to patients 
presenting with head and neck BCC or SCC and 
precludes the post treatment disfigurement often 
encountered from surgery or from use of other more 
options. Beta-emitting radioisotopes have also been 
evaluated for tropical treatment (brachytherapy) of 
basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC), the more common generally non-
malignant non-melanoma forms of skin cancer. Such 
external applications of 188Re are conducted as a 
device rather than an administered radiopharma- 
ceutical, representing regulatory approval along a 
different path. One important parameter is the soft 
tissue penetration of beta penetration, and these 
values for several beta-emitting radioisotopes of 
interest for this application are illustrated in Figure 6, in 
comparison to some other beta-, alpha- and Auger-
emitting therapeutic radioisotopes of current interest. 
188Rhenium is well suited for this application since 
radiation should reach an average tissue depth of 
about 3 mm. Application of beta-emitting radioisotope 
impregnated materials to basal cell and squamous cell 
carcinomas, particularly of the face and neck, has 
practical appeal and benefits, for instance, in 
comparison to the time consuming and invasive “Mohs” 
surgical technique. 
 
Figure 6: Comparison of estimated soft tissue penetration as 
a function of particle end-point energy of examples of beta-
emitting radioisotopes. 
The very common occurrence of BCC and SCC skin 
cancers has thus catalyzed the evaluation of a large 
variety of treatment approaches which would be 
effective but which would preclude disfigurement, 
especially for cancers of the head and neck. While the 
Mohs surgical excision technique has been practiced 
for some time, the simple use of brachytherapy or 
external beam therapy using gamma rays X-rays or 
electrons for treatment of basal cell and squamous cell 
carcinomas, are attractive radiation therapy techniques 
which offer simplicity, the general avoidance of 
disfigurement and other technical advantages. While 
exceptional precision is required for the excision of 
melanoma lesions, dangerous metastases are 
generally not an issue for treatment of basal cell and 
squamous cell carcinomas, and the use of ionizing 
radiation is very effective. One approach is the use of 
radioactive patches, which is a simpler and non-
invasive treatment method for those patients where 
traditionally therapeutic modalities would lead potential 
to scarring and disfigurement. Several beta-emitting 
radioisotopes have been evaluated for therapy of non-
melanoma skin cancer (Table 2), including 166holmium 
(166Ho), 32Phosphorus (32P), 188rhenium (188Re) and 
90yttrium- (90Y), which are generally embedded in 
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patches which are directly applied to the cancerous 
area. Because of attractive radionuclidic properties and 
availability from an on demand generators system, a 
number of studies have evaluated use of 188Re patches 
in both preclinical, and more recently, clinical settings. 
In one study, treatment of superficial experimental 
melanoma tumors induced in a C57BL/6 mouse model 
with 188Re bandage [204] tumor regression and delay 
of tumor growth was observed in all treated animals as 
a function of radiation dose. In another animal study, 
188Re-labeled paper was used and successful 
treatment of mouse skin cancer and mouse sarcoma 
was demonstrated [205]. 
Use of homogeneously 188Re imbedded 
nitrocellulose paper [204] was an early pre-clinical 
study which evaluated use of 188Re for topical 
treatment of superficial skin cancer, where 188Re-tin 
colloid was filtered through nitrocellulose filter paper 
following stannous chloride reduction of 188Re sodium 
perrhenate [204]. The nitrocellulose paper was then 
contacted to acetone-soaked gauze to dissolve the 
nitrocellulose and bind the 188Re-tin colloid to the gauze 
pad, and subsequent studies established the stability 
and tight binding of the 188Re-bound gauze preparation. 
Tumor growth in BALBc and ICR mice (5-7 mm 
diameter, 1-3 mm thick) formed after inoculation with 
RT101 mouse skin cancer and sarcoma 180 cell lines 
treated with 188Re-labeled paper preparation sections 
was evaluated after delivery of an estimated 50 and 
100 Gy doses. While 60-75% remission was observed 
after four weeks in animals with sarcomas, complete 
tumor remission was seen in animals with RT101 
tumors after this time period. These early data 
demonstrated that further topical brachytherapy studies 
with 188Re applicators may be a simple and effective 
technique for therapy of non-melanoma skin cancer. 
Because of anatomical locations which may be 
difficult to adequately reconstruct following surgical 
removal of basal cell and squamous cell carcinomas of 
the face and neck, the clinical use of locally applied 
beta-emitting radioisotopes thus offered an innovative 
alternative simple and inexpensive strategy [205-210], 
and 188Re impregnated patches and creams have 
demonstrated dramatic removal of such lesions without 
accompanying disfigurement. Wider use of this 
promising technique is expanding and the required 
technology and applicators are available (OncoBeta® 
GmbH, Garching, Germany). Dose prescription is 
based on the beta penetration at the skin surface and 
the time of treatment. Figure 7 illustrates the dose 
penetration curves which have been developed for use 
of the 188Re cream [206]. The 188Re cream is applied 
over the tumor surface for a specified time determined 
by the dose prescription. 
This approach is based on use of a 188Re-
impregnated cream for topical application which had 
initially been commercially developed as the “ITM 
Rhenium-SCT™” (Skin Cancer Therapy) which was 
initially available from the ITG portfolio. Results of 
reported studies have demonstrated this to be an 
excellent approach for treatment of non-melanoma skin 
cancers and the results of several clinical studies have 
been published [206-209]. An important advantage of 
this strategy is that application of the cream 
automatically matches the skin conformity and does 
require pre-preparation of a radioactive applicator to 
match the anatomy of the therapy site. Instead, the 
Table 2: Representative Beta-emitting Radioisotopes Evaluated for Superficial Brachytherapy of BCC and SCC Skin 
Cancer 
Radioisotope Tissue Irradiation Parameters 
 Radioactive Emission Emax MeV 
Half-Life  Average mm Soft Tissue Penetration 
198Gold βmax 0.96 2.7 days ≈ 4.2 mm 
166Holmium βmax 1.85 26.8 hours ≈ 0.8 mm 
31Iodine βmax 0.606 8.02 days ≈ 4.2 mm 
192Iridium γmax 0.672 (i.e. no β’s) 73.8 days ≈ 4.1 mm  
32Phosphorus βmax 1.71 14.29 days ≈ 8 mm 
188Rhenium βmax 2.12 16.9 days ≈ 9 mm 
90Yttrium βmax 2.3 64.1 hours ≈10 mm 
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188Re is embedded in a cream which is then applied to 
the treatment site, previously covered with surgical 
tape, with a special applicator. The Rhenium-SCT® is 
CE Labeled as a Medical Device and is now available 
from OncoBeta® GmbH who provide all the required 
hardware (treatment unit and applicator, Figures 8 and 
9), as well as disposables and accessories needed for 
the treatment. Radiation doses to patient and staff are 
low (0.05 – 0.1 mSv for the patient and in average 0.7 
µSv per treatment for the operators) using the 
OncoBeta® system. 
The results of studies reportedly conducted in over 
1,000 patients in Italy have provided excellent results 
[Data provided by OncoBeta®] and have demonstrated 
good therapeutic efficacy of 188Re for treatment of non-
melanoma skin cancer. In addition to the on-demand 
availability of 188Re from the 188W/188Re generator, 
which has a useful shelf-life of several months, the 
short 16.9 hour half-life and high dose rate from the 
2.12 MeV beta emission are important properties which 
allow outpatient treatment for use of the 188Re 
OncoBeta® technology. Before and after treatment 
example of the use of this technology for treatment of 
an ulcerated BCC of the scalp is illustrated in  
Figure 10. 
For the OncoBeta® “cream” preparation, 188Re-
sodium perrhenate is converted to a nano-colloid (200-
800 microns) by use of a “kit” consisting of an HCl 
solution of thioacetamide and polyvinylpyrrolidone, 
which is then homogeneously combined with a 
synthetic acrylic resin material [206]. The treatment 
area is outlined visually and using dermoscopy 
epiluminescence to include a margin of typically 2-3 
mm. Available literature from the OncoBeta company 
report that 188Re treatment of over 700 patients with 
BCC and SCC resulted in an overall 85% success rate. 
One recent published study enrolled 53 patients who 
presented with histologically confirmed basal cell 
(BCC) and squamous cell (SCC) carcinoma [205-208]. 
Almost all patients undergoing treatment have had 
 
Figure 7: Examples of three human tissue dose adsorption 
curves used for 188Re dose prescription using the ITG 188Re-
SCT™ applicator system (Courtesy of A. Sedda and C. 
Cipriani, Rome/Celano). 
 
Figure 8: Cartoon illustrating use of the OncoBeta® 
applicator device for dispensing the 188Re-labeled cream to 
the surface of a non-melanoma skin carcinoma and 
irradiation to a depth of about 3 mm with the 2.12 MeV beta 
particles emitted from 188Re decay (Courtesy of Dr. Thomas 
Wendler, OncoBeta®, Garching, Germany). 
 
 
Figure 9: Dispensing tube for the OncoBeta® applicator 
device filled with the 188Re-labeled cream which is fitted into 
the dispenser unit sown in Figure 7. The exposed brush 
shown in the lower photo is then used to dispense the 188Re 
cream onto the tumor surface (Courtesy of Dr. Thomas 
Wendler, OncoBeta®, Garching, Germany). 
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complete remission of the treated lesions. For the 
majority of the patients (89 %) the treatment is 
conducted during a single-session. In some cases, 
depending on the depth of the lesion and the dose 
prescription, several cream applications may be 
required. The OncoBeta® system appears easy to us, 
provides impressive non disfiguring results, has now 
progressed to broader clinical application, and it is 
hopeful that this device technology will continue to be 
enthusiastically accepted and employed by the 
dermatology/oncology communities. Treatment is 
usually completed within one hour in a single session, 
is painless requiring no anesthetic and has exhibited 
high response and low recurrence in treated patients. 
OncoBeta® GmbH is currently further developing, 
certifying and commercializing this 188Re-based skin 
cancer treatment. The technology is evidently routinely 
used in Italy as a CE-certified medical device and 
hopefully evolving clinical studies with this technology 
in Europe will further evaluate its benefit in larger 
patient populations 
3.2. Application of 188Rhenium Labeled Agents for 
Therapy of Infectious Disease 
Another unique application being pursued with 
188Re involves in vivo targeting of infectious disease 
with radiolabeled peptides [210-225]. Radioimmuno-
targeting of antibodies radiolabeled with beta (188Re) 
and alpha bismuth-213, 213Bi)-emitting radioisotopes is 
a unique approach designed for the potential treatment 
of infectious disease. Target organisms include 
bacterial infections [217, 223], fungal infections 
(Cryptococcus neoformans, Histoplasma capsulatum) 
[210, 215-216], viral [211-215] and even HIV infections 
[217]. Although this seminal approach developed for 
treatment of certain infectious diseases with 
therapeutic radioisotopes has not entered the clinical 
arena, such a strategy may offer important possibilities 
for clinical therapy of special cases of viral and fungal 
disease which cannot be adequately treated by 
conventional technologies. Although the results of 
these impressive pre-clinical studies evaluating the 
effectiveness of treating infectious disease with 188Re-
labeled antibodies, at the current time no clinical 
studies have yet been reported. These authors have 
also explored a similar approach for patient treatment 
of metastatic melanoma with the 188Re-PT1-6D2 
antibody targeted to melanin expressed on the surface 
of melanoma tumor cells [226]. 
DISCUSSION 
This goal of this paper has been to present a brief 
overview of the important established and developing 
clinical applications of 188Re which have been pursued 
in nuclear medicine, oncology and for other 
applications. Impressive results describing new 188Re 
radiolabeling strategies, radiopharmaceutical develop- 
ments, preclinical testing and clinical introduction of 
new 188Re-laebed therapeutic agents have been 
reported over the last three decades. More extensive 
information on the development and clinical evaluation 
of 188Re-labeled agents can be found in several 
reviews [106, 196, 227-230]. Current principal clinical 
efforts in this area are focused on the use of 188Re-
HEDP for bone pain palliation and the use of a variety 
of 188Re-labeled arterial occlusive agents for therapy of 
inoperable HCC. Other developing future important 
clinical applications using 188Re are expected to evolve 
for the therapy of non-melanoma skin cancer, unique 
treatment strategies for infectious disease, for 
augmentation of the therapeutic effectiveness of 
chemotherapeutic agents for cancer therapy, and 
possible development of new 188Re-PSMA targeting 
agents for the treatment of recurring prostate cancer.  
 
Figure 10: Example of an ulcerated scalp BCC before, and after 382 days following a single treatment with 188Re (Courtesy of 
A. Sedda and C. Cipriani, Rome/Celano). 
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CONCLUSIONS 
The routine, widespread use of 188Re-labeled 
therapeutic radiopharmaceuticals in clinical practice will 
be dependent on regulatory issues and the expected 
increased availability of GMP sterile, pyrogen free 
188W/188Re generators and labeling substrate “kits”. In 
addition, the availability of 188Re in centralized 
radiopharmacies and the further development and 
commercial availability of regulatory approved 188Re 
agents are important factors which are expected to 
evolve as interest in the clinical use of 188Re increases. 
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